Aditxt, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aditxt, Inc. operates as a biotechnology enterprise dedicated to advancing health through innovative approaches to immune system management. The company develops specialized platforms focused on understanding and modulating immune responses. Its AditxtScore technology provides comprehensive immune profiling, enabling individuals to monitor and comprehend their immune status in relation to potential threats or internal dysregulation. Additionally, Aditxt is pioneering Apoptotic DNA Immunotherapy (ADI), a nucleic acid-based system designed to re-educate the immune system to foster natural tolerance toward the body's own tissues. This includes the development of therapeutic candidates like ADI-100 for applications in organ transplantation, skin grafting, and various autoimmune conditions such as psoriasis, type 1 diabetes, and multiple sclerosis, with programs advancing toward clinical trials. The company has also expanded its portfolio with subsidiaries such as Pearsanta, which is engaged in personalized diagnostics for conditions including early cancer detection and women's health, alongside Adivir, focused on infectious diseases. Aditxt functions as a social innovation platform, fostering collaboration with research institutions and industry partners. The company holds licensing agreements with institutions including Loma Linda University and Leland Stanford Junior University. Originally known as ADiTx Therapeutics, Inc., the company adopted its current name in July 2021. Incorporated in 2017, Aditxt, Inc. is headquartered in Mountain View, California.
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Drop in Short Interest
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026
Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA)
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 18.8% in February
Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Decrease in Short Interest
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and Aditxt (NASDAQ:ADTX)
Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Declines By 31.2%
Stock Market Today: S&P 500, Dow Futures Gain As Jobs Data Weighs On Outlook—Lennar, Micron Technology, Children's Place In Focus
What Sparked Aditxt (ADTX) Stock's 52% After‑Hours Surge?
Critical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX)
Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Growth in Short Interest
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025